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Bacterial fibronectin-binding proteins 
(FnBPs) contain a large intrinsically-
disordered region (IDR) that mediates 
adhesion of bacteria to host tissues, and 
invasion of host cells, through binding to 
fibronectin (Fn). These FnBP IDRs consist of 
Fn-binding repeats (FnBRs) that form a 
highly extended tandem β-zipper interaction 
on binding to the N-terminal domain of Fn. 
Several FnBR residues are highly conserved 
across bacterial species, and here we 
investigate their contribution to the 
interaction. Mutation of these residues to 
alanine in SfbI-5 (a disordered FnBR from 
the human pathogen Streptococcus pyogenes) 
reduced binding but for each residue the 
change in free energy of binding was <2 
kcal/mol. The structure of an SfbI-5 peptide 
in complex with the second and third F1-
modules from Fn confirms that the conserved 
FnBR residues play equivalent functional 
roles across bacterial species. Thus, in SfbI-5, 
the binding energy for the tandem β-zipper 
interaction with Fn is distributed across the 
interface rather than concentrated in a small 
number of “hot spot” residues that are 
frequently observed in the interactions of 
folded proteins. We propose that this might 
be a common feature of the interactions of 
IDRs, and is likely to pose a challenge for the 
development of small molecule inhibitors of 
FnBP-mediated adhesion to and invasion of 
host cells.  
In the last twenty years there has been 
increasing recognition of the functional 
importance of regions of protein sequence that 
lack a stable tertiary fold under physiological 
conditions (1,2). Previously the “structure-
function paradigm” asserted that a protein must 
be stably folded to be functional. However it has 
since been shown that intrinsically disordered 
regions (IDRs) are involved in key molecular 
recognition events in both physiological (3) and 
pathological processes (4) and that IDRs often 
become structured on binding (5). 
Our previous work has shown that cell-wall 
attached proteins expressed by some 
staphylococci and streptococci species and also 
the Lyme disease-causing spirochete, Borrelia 
burgdorferi, contain IDRs which bind the 
protein fibronectin (Fn) through a highly unusual 
mechanism of protein-protein recognition which 
we called a tandem β-zipper (6-11). This work 
investigates the thermodynamics of this 
interaction by studying the binding of Fn to SfbI, 
a Fn-binding protein (FnBP) from Streptococcus 
pyogenes. 
Fn is a chordate glycoprotein (12). It is found 
as a disulfide-linked dimer in human plasma and 
in an insoluble fibrillar form as a component of 
extracellular matrices. Fn plays an essential role 
in development (13,14) and in other processes 
requiring cell migration, such as wound healing 
and tissue remodeling (15). Fn is a modular 
protein and the N-terminal domain (NTD) 
contains a string of five Fn type I (F1) modules 
(1−5F1) whose sequences are highly conserved 
across vertebrates (16). IDRs within bacterial 
FnBPs interact with these F1 modules.  
S. pyogenes is an important human pathogen 
that causes common infections of the throat and 
skin such as pharyngitis and impetigo, and can 
also cause more severe invasive infections such 
as streptococcal toxic shock syndrome and 
necrotizing fasciitis (reviewed in (17)). SfbI 
mediates bacterial invasion of epithelial cells 
and endothelial cells (18-20) by binding to Fn, 
which acts as a bridge between SfbI and host cell 
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integrins. Internalization might allow 
S. pyogenes to avoid anti-microbial drugs and 
host-defense mechanisms (reviewed in (21) and 
(22)) and, thus, is a potential target for new 
therapeutics. 
Biophysical studies have shown that an FnBP 
from Staphylococcus aureus contains a series of 
intrinsically disordered Fn-binding repeats 
(FnBRs) that undergo a disorder-to-order 
transition on binding either 2−4F1 or 2−5F1 from 
the NTD of Fn (10,23,24). In this tandem 
β-zipper interaction, the FnBR extends the triple-
stranded anti-parallel β-sheet of sequential F1 
modules by forming an additional strand anti-
parallel to the C-terminal strand (strand E) of 
each F1 module (7,25). SfbI from S. pyogenes 
contains five FnBRs that each bind the NTD of 
Fn (7,8,22). SfbI-5, the most C-terminal FnBR 
also has a 1F1-binding motif and can, therefore, 
bind all five F1 modules (1−5F1). To date, 1F1-
binding motifs have only been identified in C-
terminal streptococcal FnBRs (7,22). 
The thermodynamics of protein-protein 
interactions involving two folded proteins have 
been well-studied. Mutational analyses show 
that the free-energy of binding is often 
concentrated within a few hot spot residues (26) 
(change in Gibbs free energy of binding, ∆∆G°, 
on mutation of >2 kcal/mol) rather than being 
distributed evenly across the interface (27). The 
ability to identify hot spot residues is particularly 
important for the discovery of drugs that target 
protein-protein interactions (28) and there are 
now a number of web servers that will perform 
such predictions (29-31). Much less is known 
about the thermodynamics of the interactions of 
IDRs. 
In this study we demonstrate that SfbI-5 is an 
IDR. We use a Hidden Markov Model (HMM) 
to identify the most conserved FnBR residues 
across bacterial species. We show that for the 
NTD:SfbI-5 tandem β-zipper interaction, 
residues that are highly conserved across FnBRs, 
and that form very similar intermolecular 
interactions in NTD:FnBR complexes across 
bacterial species, are not hot spot residues. 
Therefore, unlike many interfaces formed 
between folded proteins, for SfbI-5 the binding 
energy is distributed across the interface. We 
suggest this might be a feature of the rather 
extended interactions that many IDRs form 
relative to folded proteins (32). The distributed 
energy of binding will pose a challenge to the 
development of small molecules that inhibit 





Proteins, Proteolytic fragments, Synthetic 
Peptides, Protein Expression and Purification –
The synthetic peptide PyTT5, corresponding to 
residues 560–577 of SfbI (UniProt accession 
Q01924), was purchased from Alta Bioscience 
(Birmingham, UK). The N- and C-termini were 
capped by acetylation and amidation, 
respectively. Human plasma Fn was purchased 
from Sigma Aldrich (product no. F0895). The N-
terminal domain from human plasma Fn, 
containing 1−5F1, was purchased as a 30 kDa 
proteolytic fragment from Sigma Aldrich 
(product no. F9911) and is referred to as pNTD 
herein. The N- and C-termini were determined 
by mass spectrometry (MS) using an apex ultra 
FTMS (Bruker Daltonics). 
2F13F1 (residues 62–151 of mature human 
Fn) was expressed in Pichia pastoris and 
purified using procedures similar to those 
described previously (7,33). SfbI-5 
(corresponding to residues 542–591 of SfbI) was 
expressed as a recombinant glutathione S-
transferase (GST) fusion using the pGEX-5X-
SfbI-5 construct described previously (7). 
Escherichia coli BL21 Gold competent cells 
(Stratagene) were transformed with pGEX-5X-
SfbI-5 using a rapid protocol (34). A culture of a 
single transformed colony inoculated into LB-
Amp broth (1% (w/v) tryptone, 0.5% (w/v) yeast 
extract, 1% NaCl (w/v), 100 µg/ml ampicillin) 
was grown for ~18 h at 37°C and then diluted 
into LB-Amp broth and incubated with shaking 
at either 30°C or 37°C. Cultures were induced to 
over-express the GST fusion with isopropyl β-D-
thiogalactopyranoside when the optical density 
at 600 nm was between 0.6 and 1.2, and were 
then grown for a further 17 h (30°C) or 3 h 
(37°C). The GST fusion protein was purified 
from cleared cell lysates using glutathione 
Sepharose (GE Healthcare).  
For ITC and NMR experiments, SfbI-5 was 
cleaved from GST with Factor Xa (New England 
Biolabs), purified by reversed-phase high 
performance liquid chromatography (8) and 
lyophilized. The mass of the purified product 
was confirmed by MS. 15N, 13C-labelled SfbI-5 
was produced using similar methods but using 
isotope-labelled minimal media. 
Site-directed Mutagenesis – All SfbI-5 
mutants were created through site-directed 
mutagenesis of pGEX-5X-SfbI-5 using the 
3 
 
Quikchange II mutagenesis kit (Stratagene), and 
the primers in Supplemental Table 1. In-house 
DNA sequencing confirmed the presence of 
mutations. SfbI-5 mutants were expressed, 
purified and lyophilized as for wild type SfbI-5, 
and their masses confirmed by MS. 
Isothermal Titration Calorimetry (ITC) – The 
binding of pNTD to SfbI-5 and SfbI-5 mutants 
was measured in PBS (140 mM NaCl, 2.7 mM 
KCl, 10 mM Na2PO4, 1.8 mM KH2PO4) at 37°C 
using a VP-ITC microcalorimeter (MicroCal) 
and a procedure very similar to that reported 
previously (8). For each SfbI-5 peptide, an ITC 
experiment consisted of a binding titration and a 
control titration; the SfbI-5 peptide titrated into 
PBS with or without pNTD, respectively. The 
experiments were performed with pNTD (1.4–
4 µM) in the cell and the peptide (20–50 µM) in 
the syringe. The experiments with the following 
SfbI-5 peptides were performed twice: SfbI-5, 
F554A, K556A, K556E, D574A and T575A; 
and those with T558A were performed three 
times. Data were analyzed and fitted to a single 
site binding model using non-linear regression 
analysis in Origin 7.0 software (MicroCal). 
The concentration of pNTD was determined 
by absorbance at 280 nm using a theoretical 
extinction coefficient, based on the amino acid 
sequence, of 63130 M-1 cm-1. The concentration 
of the SfbI-5 peptide was initially estimated 
from the weight of lyophilized material and then 
determined for one syringe sample for the 
following SfbI-5 peptides by quantitative amino 
acid analysis (Alta Bioscience, Birmingham): 
SfbI-5, F554A, K556A, K556E, T558A, and 
D574A. Use of these peptide concentrations 
resulted in molar ratio of binding (n) values 
within 12% of 1.0. Thus, for all other titrations, 
the peptide concentrations were corrected during 
analysis to give an n value of 1. Heats of dilution 
were either the injection of the appropriate 
peptide into buffer or the average peak area of 
the last five or ten injections from the binding 
titration. For those SfbI-5 mutants whose ITC 
experiments were repeated, the mean value of 
each parameter was used for subsequent 
analysis. 
NMR Spectroscopy – A standard suite of 
triple-resonance experiments was performed for 
sequential assignment of 15N, 13C-labelled SfbI-5 
(1 mM, pH 5.5, 10% (v/v) D2O, 0.02% (w/v) 
NaN3). All were acquired using standard Bruker 
pulse sequences on a Bruker AVII 700 MHz 
spectrometer equipped with a triple resonance 
(HCN) probe and z-axis gradients at 25°C. Data 
were processed using NMRPipe (35) and 
analyzed using CCPN Analysis (36). 
Secondary structure propensity (SSP) was 
calculated from the assigned chemical shifts of 
the SfbI-5 1HN, 15NH, 13Cα, 13Cβ and 13C′ nuclei 
(Supplemental Table 2) using the SSP Perl script 
kindly made available for download by Marsh et 
al. (37). The input used for the script was the 
experimentally-determined SfbI-5 chemical 
shifts and the statistically-derived random coil 
dataset from Wang and Jardetzky (38). 
Appropriate sequence correction values for the 
random coil dataset (38) were added to the 
corresponding observed SfbI-5 chemical shifts 
before SSP score calculation.  
X-ray Crystallography – Crystals of 
2F13F1:PyTT5 (0.3 mM/~3.5 mM, pH 7.7) were 
grown using sitting drop vapour diffusion from a 
1:1 dilution with the well solution. The well 
solution was either 20 mM MgCl2, 0.1 M 
HEPES pH 7.5, 22% w/v polyacrylic acid or 0.1 
M Tris pH 7.0, 1.5 M (NH4)2SO4 for the lower 
and higher resolution data, respectively. Crystals 
were flash-cooled in liquid nitrogen using 20% 
or 30% (v/v) glycerol as the cryoprotectant. 
Data Collection and Refinement – The lower 
resolution data were collected in-house at 120 K 
and the higher resolution data at 100 K at the 
European Synchrotron Radiation Facility on the 
ID23-1 beamline. Statistics are provided in 
Supplemental Table 3. Data were processed and 
scaled using MOSFLM/SCALA (39-41). 
Successful solution of the lower resolution data 
was obtained by molecular replacement using 
models of 2F1 and 3F1 (pdb code 2RKZ) (25), 
searched for separately within Phaser (42). This 
structure was refined as described previously 
(25) and was used (without PyTT5) as the 
starting point for refinement of the higher 
resolution data using REFMAC (43).  
Creation of Hidden Markov Model – A 
profile HMM (44) was assembled using the 
sequences of known FnBRs (22) and using 
structural data (25) to inform where gaps in the 
alignment would be more likely. The HMM was 
used to search for other FnBRs in the UniRef90 
sequence database (45). A set of non-redundant 
FnBRs was created from those identified in the 
search, in which each FnBR had no more than 
70% pairwise identity to any other FnBR in the 
set. An HMM representing the non-redundant 
FnBRs was used in a second search of the 
database. This iterative process was repeated 
three times, until no further FnBRs were 
identified. An HMM logo was produced (46) 
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using a final HMM of all non-identical FnBRs. 
Model of 1−5F1:SfbI-5 – The model of 
1-5F1:SfbI-5 was built from the structure of 
2F13F1:PyTT5, an alignment between 4F15F1 
and S. aureus FnBPA peptide structures (pdb 
codes 2RKY and 2RL0) (25), and 1F1 and the 
1F1-binding region from the structure of 1F12F1 
in complex with B3T (pdb code 1O9A) (7) using 
the program Modeller (47). The 1F12F1 interface 
is not well-defined even in the presence of 
peptide (7). 
Surface Plasmon Resonance (SPR) – 
Interactions of SfbI-5 with human Fn and pNTD 
were studied using SPR. Binding studies were 
performed using a BIAcore T100 instrument 
(GE Healthcare) at 25°C. GST-tagged wild-type 
or mutant (T558A) SfbI-5 was immobilized onto 
the experimental flow cell of a certified C1 
sensor chip (GE Healthcare) by amine coupling 
using N-hydroxysuccinimide (NHS) and ethyl 
(dimethylaminopropyl) carbodiimide (EDC). 
Ethanolamine was subsequently used to block 
the surface. The reference flow cell underwent 
an identical but blank immobilization and 
blocking protocol. The SPR running buffer was 
HBSP (10 mM HEPES pH 7.4, 150 mM NaCl, 
0.05% (v/v) polysorbate 20). Flow rates of 
20 µl/min and 30 µl/min were used for data 
acquisition and regeneration, respectively. The 
analyte contact and dissociation times were 
180 s and 600 s or 1200 s, respectively. The 
longer dissociation time was required for the 
interaction of wild-type SfbI-5 with Fn, to 
ensure dissociation of a significant amount of 
analyte from the ligand. Regeneration contact 
and stabilization times were 540 s and 3000 s, 
respectively. 0.1 M NaOH was used for 
regeneration. A kinetic data series contained 
sensorgrams measured for seven or eight 
sequential two-fold analyte dilutions from 
13.9 nM for both Fn and pNTD. Kinetic data 
series were fitted to a Langmuir 1:1 binding 
model by Biacore T100 Evaluation Software 
(GE Healthcare) using a constant, zero bulk 
refractive index parameter. An upper limit for 
analyte concentration for sensorgram analysis 
was determined to ensure reliable curve-fitting 
indicated by low χ2 values. For the interaction 
between pNTD and SfbI-5 T558A, steady state 
affinity analysis was used to determine the 
binding affinity by Biacore T100 Evaluation 





SfbI-5 is an IDR – SfbI-5 binds to pNTD with 
the highest affinity (Kd ~3nM at 37°C) (8) of the 
FnBRs studied to date. Although SfbI-5 is 
predicted to be an IDR based on its sequence, 
this has not been confirmed experimentally. In 
the absence of pNTD, the 15N-1H HSQC NMR 
spectrum of 15N, 13C-labelled SfbI-5 has the 
narrow line-widths and low chemical shift 
dispersion in the 1H dimension typical of an IDR 
(Fig. 1A). To confirm this observation, standard 
NMR methods were used to assign chemical 
shifts to the 1HN, 15NH, 13Cα, 13Cβ and 13C′ nuclei 
(Supplemental Table 2). The secondary structure 
propensity for each residue was determined by 
calculation of its SSP score, using the assigned 
chemical shifts and those predicted for a 
sequence-corrected random coil (37,38) (Fig. 
1B).  
No evidence of stable secondary structure, 
nor significant SSP, was detected in the 2−5F1 
binding region of SfbI-5. This is consistent with 
previous circular dichroism results that 
streptococcal and staphylococcal FnBRs are 
IDRs (48), and also with a previous NMR 
analysis of an FnBR-containing region in S. 
aureus FnBPA (6). However, unlike other 
FnBRs in SfbI, SfbI-5 contains a 1F1-binding 
region (residues 577–588) (7) and this region has 
SSP for β-strand conformations (Fig. 1B). In 
particular, residues 580–584 have an SSP score 
of less than −0.3, indicating that within this 
region more than a third of the SfbI-5 molecules 
exhibit φ and ψ angles typical of β-strand at any 
given time. This provides a plausible explanation 
for our previous observation that the 1F12F1-
binding motif from SfbI-5 bound with higher 
affinity than SfbI peptides that bind 2F13F1 or 
4F15F1 (8). 
Conservation of FnBR residues – Fig. 2 
shows an HMM logo (46) assembled from an 
alignment of all non-redundant staphylococcal, 
streptococcal and spirochetal FnBRs identified 
in the sequence databases. Fig. 2 shows that, 
particularly in the FnBR region that binds 
2F13F1, there are residues that are highly 
conserved across all FnBRs.  
Effect of Mutation of Conserved FnBR 
Residues on Affinity of the Interaction of SfbI-5 
with 1−5F1 – The effect of mutating conserved 
SfbI-5 residues on the binding of SfbI-5 to 1−5F1 
was investigated using ITC. The 2F1- and 4F1-
binding regions contain the most conserved 
FnBR residues (Fig. 2). Additionally, we have 
previously shown that, of the 2−5F1-binding 
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regions, only the 2F1- and 4F1-binding regions 
show significant binding to F1 module pairs that 
contain their target F1 module (8). Thus, we 
focused the mutation analysis on these regions 
and on the highly conserved Gly in the 3F1-
binding region. Also, for comparison, we 
mutated two residues with lower levels of 
conservation; one in the 2F1- and one in the 3F1-
binding region.  
As can be observed from Table 1 and Fig. 3, 
when conserved residues in SfbI-5 were mutated 
to alanine, the binding became weaker relative to 
wild-type SfbI-5. In the one case where a residue 
in SfbI-5 that was not the consensus FnBR 
residue for that position (Fig. 2) was mutated to 
the consensus residue (K556E), the binding was 
significantly tighter relative to wild-type SfbI-5. 
Thus, overall, these results are consistent with 
the HMM logo in Fig. 2. However, while 
mutation of all the conserved residues weakened 
the interaction, for even the most conserved 
FnBR residues, the effect of mutation was 
relatively modest when compared with the effect 
of mutating hot spot residues on the interactions 
of folded proteins (defined here as those that 
contribute more than 2 kcal/mol to the 
interaction (26)).  
Key interactions are conserved between 
S. aureus FnBPA and S. pyogenes SfbI in 
binding to 2F13F1 – To test whether residues 
conserved across FnBRs play the same 
functional role in the binding of different 
organisms to Fn, we determined the structure of 
2F13F1 in complex with PyTT5 (the 2F13F1-
binding peptide from SfbI-5) and compared it to 
our previously determined structures of 
homologous peptides from S. aureus FnBPA in 
complex with 2F13F1 (2F13F1:STATT1 and 
2F13F1:STATT5; pdb codes 2RKZ and 3CAL, 
respectively (25)).  
Fig. 4 shows the 1.7 Å resolution structure of 
PyTT5 in complex with 2F13F1 (crystallographic 
parameters are provided in Supplemental Table 
3). It is clear that PyTT5 binds the E strands of 
2F1 and 3F1 through a tandem β-zipper 
mechanism (Fig. 4A), with PyTT5 residues 562–
565 and 570–574 adopting φ and ψ angles 
typical of β-strand. As expected, there is little 
difference in the F1 module structures; 
comparison of the structure with that of 
2F13F1:STATT1 shows a root mean squared 
deviation of 2.11 Å between 2F13F1 in the two 
structures. 
The side-chains of the PyTT5 3F1-binding 
region (residues 560–565) interact with 3F1 
primarily via van der Waals contacts, with M562 
contacting L134 and R125 in 3F1, and F565 
stacking against aliphatic side-chain atoms of 
K143 and E145 (Fig. 4C). Furthermore, a 
glycine at position 564 allows PyTT5 to adopt a 
β-strand conformation without a steric clash with 
W146 in 3F1 (Fig. 4C). Thus, the highly 
conserved glycine identified in Fig. 2 performs 
the same function in this structure as in the two 
structures of 2F13F1 with S. aureus peptides 
(25). 
The PyTT5 linker region (residues 566–569) 
does not loop away from 2F13F1 as in the 
2F13F1:STATT1 and 2F13F1:STATT5 structures 
(25), although it is the same length as the linker 
region in STATT5 (25). Instead, the PyTT5 
linker binds to the interface between 2F1 and 3F1 
primarily via hydrogen bonds; the side-chains of 
bacterial residues S566 and E567 participate in 
hydrogen bond networks involving residues in 
both 2F1 and 3F1 (Fig. 4C). 
The PyTT5 2F1-binding region (residues 
570–577) binds to 2F1 via both van der Waals 
and hydrogen bond interactions. The two key 
van der Waals contacts are between the side-
chains of the bacterial residues I571 and D574 
and the side-chains of W90 and R99 of 2F1, 
respectively. T570 forms a hydrogen bond with 
the side-chain of T105 in 2F1, adopting a 
staggered conformation favoured in β-sheets 
(49). The side-chain of E573 exists in two 
conformations in both 2F13F1:PyTT5 complexes 
in the asymmetric unit with approximately 50% 
occupancy in each conformation. One of the 
conformations results in a salt bridge to the side-
chain of R83 in 2F1 (Fig. 4D) as found for the 
corresponding side-chain in both complexes of 
S. aureus peptides with 2F13F1 (25). The second 
E573 side-chain conformation forms a hydrogen 
bond to the carbonyl group of D574 via a 
bridging water molecule (Fig. 4D). The side-
chain of D574 forms a salt bridge with both 
R101 and R99, and T575 forms hydrogen bonds 
to the backbone atoms of G100 and F67, 
although the latter is via a bridging water 
molecule (Fig. 4D). Therefore, the PyTT5 
residues corresponding to the conserved ‘E-
(D/E)-(T/S)’ motif identified in Fig. 2 form 
interactions in the complex that are very similar 
to those of the corresponding residues in the 
2F13F1:STATT1 and 2F13F1:STATT5 
complexes (25). 
PyTT5 efficiently forms an extended interface 
with 2F13F1 – The extent of the interface 
between PyTT5 and 2F13F1 was analysed using 
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ProFace (50). A protein interface can be divided 
into two categories at both the atom and residue 
level (51,52). At the atom level, the interface can 
be divided into buried and accessible interface 
atoms, where buried atoms lose all accessible 
surface area (ASA) on complex formation and 
accessible atoms lose some ASA. The ProFace 
analysis showed that every residue of PyTT5 is 
involved in the interface with 2F13F1, with at 
least one atom of each residue in PyTT5 having 
some buried surface area at the interface (Fig. 
5A; Table 2).  
At the residue level, the interface can be 
divided into core and rim residues, with core 
residues containing at least one buried interface 
atom and rim residues containing at least one 
accessible interface atom and no buried interface 
atoms. By this definition, 14 of the 18 residues 
(78%) in PyTT5 were core residues and the 
remaining residues were rim residues (32%). In 
comparison, 2F13F1 had 20 core residues (22%) 
and 18 rim residues (20%) out of a total of 89 
residues (Table 2). This indicates that each 
residue of PyTT5 contacts, on average, more 
residues of 2F13F1 than vice versa. It also 
indicates that a much greater percentage of 
PyTT5 is involved in the interface compared to 
2F13F1. This is further shown by the fact that 
40% of the ASA of PyTT5 is buried at the 
interface, compared to 17% of the ASA of 
2F13F1. Thus, PyTT5 is a very efficient ligand. 
These properties have been noted in other 
complexes involving IDRs (32,53,54).  
SfbI-5 is Predicted to Form a Large, 
Extended Interface with 1−5F1 – Structural data 
is now available for a single 1F12F1:FnBR 
peptide complex (7), three 2F13F1:FnBR (25) 
peptide complexes and two 4F15F1:FnBR 
peptide complexes (25), so it is intriguing to 
consider the extent of the interface between 
SfbI-5 and 1−5F1. ProFace analysis of a model of 
1−5F1 bound to SfbI-5 (Fig. 6) predicts that the 
total buried surface area of the interface would 
be ~5150 Å2. This is a very large interface for a 
heterocomplex. In fact, comparison between the 
predicted interface area of 1−5F1:SfbI-5 and the 
observed interface areas from a set of 
heterodimer complex structures from the Protein 
Data Bank (32) reveals that the predicted 
interface is larger than any of the interfaces in 
the dataset, and more than 1500 Å2 larger than 
the largest complex involving an IDR.  
Furthermore, 40% of the ASA of SfbI-5 is 
buried in the interface, compared to 18% of the 
ASA of 1−5F1. Thus, the reasons PyTT5 is an 
efficient ligand for binding to 2F13F1 are also 
predicted to make SfbI-5 an efficient ligand 
when in complex with 1−5F1. For a globular 
protein to bury a similar amount of surface area 
it would have to have two to three times more 
residues. Therefore, a probable biological 
advantage of the intrinsic disorder of SfbI-5 is 
large interface formation (and tight binding) 
with fewer resources committed on the part of 
S. pyogenes (53).  
Effect of Mutation of Conserved FnBR 
Residues on Affinity of the Interaction of SfbI-5 
with Fn – In vivo, SfbI-5 interacts with 1−5F1 in 
the context of intact Fn. Thus, the effect of the 
mutation of conserved FnBR residues on binding 
to plasma Fn was also determined (Fig. 7). SPR 
was first used to determine the dissociation 
constants for binding to pNTD (to compare with 
values obtained using ITC). The results were 
remarkably similar, with the T558A mutation 
causing a 19-fold reduction in the affinity when 
measured using SPR (Table 3) compared with a 
16-fold reduction in affinity when measured 
using ITC (Table 1). When binding of Fn to 
wild-type SfbI-5 and the T558A mutant were 
compared, the mutation resulted in an 
approximately five-fold reduction in the affinity. 
Thus, the T558A mutation has an even smaller 




SfbI-5 is an IDR – Comparison of the 
chemical shifts of the SfbI-5 1HN, 15NH, 13Cα, 
13Cβ and 13C′ nuclei with sequence-corrected 
random coil values revealed that SfbI-5 is an 
IDR, with no evidence of any stable secondary 
structure. However, the C-terminal 1F1-binding 
region of SfbI-5 showed significant propensity 
for β-strand formation. Based on a sequence 
alignment between SfbI-5 and the 
S. dysgalactiae FnBR peptide B3T, whose 
structure has been solved in complex with 
1F12F1 (7), the residues with high β-strand 
propensity are predicted to form a β-strand when 
bound to 1F1. Therefore, this region might be a 
preformed structural element primed for 1F1 
recognition (55). 
Conserved Residues in Streptococcal and 
Staphylococcal FnBRs Perform Similar 
Functions – The crystal structure of PyTT5 in 
complex with 2F13F1 shows that the peptide 
binds to 2F13F1 via a tandem β-zipper (Fig. 4A). 
Comparison of this structure to those of FnBPA 
peptides in complex with 2F13F1 (25) revealed 
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that residues that were conserved between these 
peptides formed similar interactions with 2F13F1. 
Given the sequence similarity between the other 
F1-binding regions of SfbI with FnBR peptides 
that have been solved in complex with 4F15F1 
and 1F12F1 (7,23,25), it is highly likely that 
SfbI-5 will bind to 1F1 and 4F15F1 via a tandem 
β-zipper. Thus, we prepared a model of the 
intact complex that highlights the extraordinary 
efficiency of the interaction (Fig. 6).  
High efficiency of extended interface 
formation has been proposed as a potential 
advantage of intrinsic disorder (53) and overall, 
interface area per IDR residue is higher in 
protein-protein heterocomplexes containing an 
IDR than for complexes containing two folded 
proteins (32). The tandem β-zipper interaction of 
SfbI-5 with 1−5F1 provides a clear demonstration 
of the efficiency of extended interface formation 
and the high affinity that can be achieved by an 
IDR. As seen previously for FnBR peptide 
interactions with F1 modules, there is little 
change in the 2F13F1 structure on PyTT5-
binding. 
Analysis of ∆∆G° values – The effect of 
mutating conserved SfbI-5 residues on the 
binding of SfbI-5 to pNTD was determined by 
calculating the ∆∆G° for binding of the SfbI-5 
mutants relative to wild-type SfbI-5 (Table 1). 
Most of the effects of the mutations can be 
rationalized from the structures based on the loss 
of buried atoms or intermolecular hydrogen 
bonds involving the mutated residue.  
Some of the effects of mutations could also 
have been predicted based on residue 
conservation (Fig. 2). For example, K556A had 
a small but favourable ∆∆G° of −0.47 kcal/mol 
and K556E had a more favourable ∆∆G° of 
−0.90 kcal/mol. This result would be predicted 
from Fig. 2 as glutamate is the most conserved 
residue at this position. Also, for G564A, the 
unfavourable change in free energy is likely 
caused by changes in surrounding interactions 
that are required to avoid a steric clash between 
the alanine side-chain and the W146 of 3F1 (Fig. 
4C). 
However, a comparison of Table 1 and Fig. 2 
shows that overall there is not a strong 
correlation between the level of conservation of 
a residue and the ∆∆G° value for mutation of 
that residue. The largest effect is observed for 
T558A, yet T558 is not, by some way, the most 
highly conserved residue. I571 and M562 were 
mutated because they are less well conserved 
(Fig. 2) and were predicted to form β-strand 
interactions with an F1 module primarily via 
backbone-backbone hydrogen bonds, a 
prediction that was confirmed by the 
2F13F1:PyTT5 structure (Fig. 4C, D). Yet the 
small ∆∆G° values (0.49 and 0.53 kcal/mol, 
respectively) for mutation for these residues are 
similar to that observed for the mutation of a 
highly conserved acidic residue (E553) in the 
conserved ‘E-(D/E)-(T/S)’ motif within the 2F1-
binding region.  
The energy of the NTD:SfbI-5interaction is 
distributed across the interface  – All mutations 
of conserved residues reduced the affinity of 
binding, but ∆∆G° values were relatively small 
(less than 2.0 kcal/mol) compared to similar 
analyses on mutating interfaces in globular 
complexes (56,57). Some analyses use a 
different threshold (e.g. ∆∆G° >1 kcal/mol (31)) 
for defining hot spot residues. The latter 
threshold would mean that four SfbI-5 residues 
were hot spots (F554, T558, G564 D574). 
Interestingly, only one of these residues is from 
the 2F1-binding region, yet it is this region that 
binds more tightly to 2F13F1 (8). However, 
regardless of the threshold chosen, it is clear 
from Table 1 that in the NTD:SfbI-5 interaction, 
the binding energy is distributed across the large 
interface rather than being concentrated in a few 
residues.  
It has been observed that hot spots tend to be 
core residues, and tend not to be rim residues. 
This is because core residues form side-chain 
interactions with the protein partner and rim 
residues act like an ‘o-ring’ and shield the core 
residues from water (58). However, the extended 
nature of PyTT5, when in complex with 2F13F1, 
means that PyTT5 does not contain an ‘o-ring’ 
of rim residues (Fig. 5B). Based on our model 
(Fig 6), intact SfbI-5, when in complex with 
1−5F1, would also lack o-ring residues. The 
reason this might lead to the absence of hot spots 
can be better understood by considering the 
interface at the level of atoms. 
At the atom level of protein-protein 
interactions, the main-chain is not directly 
affected by site-directed mutagenesis to alanine 
(51). Also, when accessible interface atoms are 
removed by mutation, they can be replaced by 
water molecules at a lower energetic cost than 
buried atoms (51). By this rationale, hot spot 
residues are likely to contain a buried interface 
atom that is deleted when the residue is mutated 
to alanine. Only two of 22 (9.1%) buried 
interface atoms in PyTT5 but 14 of 44 (32%) in 
2F13F1 fulfill these criteria. Therefore, it appears 
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the extended nature of the interface between 
SfbI-5 and 1−5F1, which is facilitated by the 
intrinsic disorder of free SfbI-5, is likely to 
preclude the presence of hot spot residues in 
SfbI-5. A more even distribution of the free 
energy of binding might be a more general 
property of complexes containing IDRs that 
have extended interfaces (32) which are unlikely 
to shield important interacting residues from 
water.  
We used the HotPOINT server (59) to 
analyse 2F13F1:PyTT5, and S. aureus FnBR 
peptides in complex with 2F13F1 (2RKZ and 
3CAL) and 4F15F1 (2RKY and 2RL0) (25) to 
predict hot spots. Consistent with our ITC 
results, this analysis also suggests an overall lack 
of hot spots in the FnBR peptides with only a 
single conserved residue in the FnBR peptides 
(and only in 2RL0) predicted to be a hot spot. 
A paradox and a challenge – We have 
shown that conserved residues in FnBRs of 
S. pyogenes and S. aureus play equivalent 
functional roles in binding to Fn and that single 
interactions can be sacrificed (in vitro) whilst 
maintaining a high affinity interaction. But why 
then are the FnBR residues so conserved? That 
is, are the conserved residues important for an 
aspect not probed by our pNTD-interaction 
assay, or are the small changes in affinity 
observed functionally significant?  
Other potential functional roles for the 
conserved residues that are not probed by the 
pNTD-binding assay are the disruption of 
intramolecular Fn interactions and/or 
maintenance of disorder in the FnBR. Long-
range intra-molecular interactions between 2−5F1 
and Fn type 3 modules (60) have recently been 
shown to mask motogenic sites within the 
collagen-binding domain of Fn. Changes in 
chemical shifts in the N-terminal strand (A 
strand) and E strands of F1 modules on F3 
module binding (60) suggests that the F3 and 
SfbI-5 binding sites on 2−5F1 partially overlap. 
The faster association rate observed for binding 
of wild-type SfbI-5 to pNTD compared to Fn 
(Table 3) is consistent with the FnBR binding 
site being somewhat cryptic in Fn. Therefore, we 
reasoned that conserved residues might play a 
role in unmasking the binding site and, thus, the 
effect of their mutation would only be observed 
when binding to Fn (rather than pNTD) was 
measured. However, the mutation that had the 
largest effect on SfbI-5 binding to pNTD 
(T558A) had an even smaller effect on the Kd for 
binding to intact Fn, suggesting that the 
interaction with Fn also lacks hot spots in the 
IDR.  
Conserved residues might also play a role in 
maintaining the disordered state of FnBRs, 
similar to conservation of structurally important 
residues in a folded protein. By definition, 
disordered proteins do not make enough 
energetically favourable intramolecular contacts 
to overcome the unfavourable entropy of folding 
into a stable tertiary structure. This is achieved 
by a characteristic amino acid composition, with 
IDRs having on average more charged and polar 
residues and fewer hydrophobic residues (61). It 
also requires each residue to limit the number of 
favourable interactions it makes with its 
neighbouring residues (62). Therefore, there 
might be selective pressure for a disorder-
promoting residue at a given position in an IDR 
depending on its neighbouring sequence. 
Whether this selective pressure exists in FnBRs 
is hard to identify given current knowledge of 
IDR residue conservation.  
Only streptococcal FnBPs, and in each case, 
only the C-terminal FnBR in the protein, 
contains a 1F1-binding motif. These 1−5F1 
binding FnBRs bind NTD with higher affinity 
than 2−5F1-binding FnBRs in SfbI (8). For 
example, in our previous study SfbI-5 bound 
pNTD with a Kd of ~2 nM at 37°C, while SfbI-4 
bound with a Kd of 60 nM at 25°C (8). While 
S. aureus FnBPs only contain 2−5F1-binding 
FnBRs, the C-terminal FnBR (FnBPA-11) also 
binds NTD with the highest affinity; Kd <1 nM 
at 25°C compared to 5 nM for FnBPA-1 (10). 
Thus, selective pressure for the maintenance of 
high affinity binding at the most C-terminal 
FnBR might operate in vivo, for example, at the 
level of integrin-mediated bacterial invasion.  
The extended, multi-domain nature of the 
tandem β-zipper interface is a plausible (and 
intuitive) explanation for the apparent absence of 
hot spots in SfbI-5. The mutation analysis of the 
NTD:SfbI-5 interaction presented here provides 
experimental support for this intuition. This 
interaction is, as yet, unusual with the only other 
reported example in LIM/Ldb interactions (54). 
However, extended interactions appear to be 
favoured by IDRs (32), and, thus, we suggest 
that IDRs in general might be more likely to 
form interactions that lack well-defined hot 
spots.  
Rational design strategies for drugs that 
target protein-protein interactions are still in the 
relatively early stages of development (28). The 
additional challenges involved in the design of 
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drugs that target interactions involving IDRs has 
recently been highlighted (63). The more even 
distribution of binding energy over the interface, 
as observed here, than is commonly observed in 
the binding of folded proteins, will add a further 
challenge; specifically for development of 
inhibitors of FnBP-mediated invasion of host 
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TABLE 1  
Thermodynamic parameters for the interaction between pNTD and SfbI-5 mutants determined by ITC 














SfbI-5 3.5 ± 0.2 −45.4 ± 0.7 −108 −11.99 ± 0.04 0.00 ± 0.06 
V552A 10.6 ± 0.8 −44.3 ± 0.2 −106 −11.30 ± 0.05 0.69 ± 0.06 
E553A 8.4 ± 0.8 −45.2 ± 0.3 −109 −11.45 ± 0.06 0.54 ± 0.08 
F554A 31.5 ± 4.9 −42.9 ± 0.7 −104 −10.63 ± 0.10 1.36 ± 0.10 
K556A 1.6 ± 0.2 −45.7 ± 1.4 −107 −12.46 ± 0.08 −0.47 ± 0.09 
K556E 0.8 ± 0.2 −49.0 ± 2.4 −116 −12.90 ± 0.18 −0.90 ± 0.18 
D557A 13.8 ± 1.0 −43.2 ± 0.2 −103 −11.14 ± 0.05 0.85 ± 0.06 
T558A 55.4 ± 2.7 −37.9 ± 1.6 −89.0 −10.29 ± 0.03 1.70 ± 0.05 
M562A 8.2 ± 0.4 −40.0 ± 0.1 −92.2 −11.46 ± 0.03 0.53 ± 0.05 
G564A 28.7 ± 2.1 −38.5 ± 0.2 −89.6 −10.69 ± 0.04 1.30 ± 0.06 
I571A 7.7 ± 0.3 −44.5 ± 0.1 −106 −11.50 ± 0.03 0.49 ± 0.05 
E573A 13.9 ± 0.8 −43.6 ± 0.2 −105 −11.14 ± 0.03 0.85 ± 0.06 
D574A 41.0 ± 5.9 −46.3 ± 1.2 −116 −10.47 ± 0.09 1.52 ± 0.10 







TABLE 2  
Analysis of the interfaces in the 2F13F1:PyTT5 complex by change in ASA on 
complex formation.  
Complex 2F13F1:PyTT5 
Molecule, chain 2F13F1, B PyTT5, D Complex 
Interface area (Å2)    
Total 851.4 1095.6 1947.0 
Core 653.1 853.0 1506.1 
Rim 241.5 242.6 484.1 
Interface area / Surface area 0.17 0.41 0.24 
Number of interface atoms    
Total 122 89 211 
Buried 44 22 66 
Accessible 78 67 145 
Number of interface residues    
Total 38 18 56 
Core 20 14 34 
Rim 18 4 22 
Fraction of non-polar atoms 0.57 0.60 0.58 
Non-polar interface area (Å2) 443.5 592.3 1035.8 
Fraction of fully buried atoms 0.36 0.25 0.31 
Local Density 36.56 32.70  
Statistics for the interface between 2F13F1 chain B and PyTT5 chain D were calculated 






TABLE 3  
Parameters for the interaction of pNTD and Fn with SfbI-5 and the T558A mutant determined using 
SPR at 25°C, pH 7.4  
Construct k1a 












pNTD                
SfbI-5  2.89   39.7  0.137 ± 0.002 −13.44 ± 0.01 0.00   
T558A  n/db   n/db  2.6 ± 0.3 −11.71 ± 0.07 1.74 ± 0.07 
Fn                
SfbI-5  0.462   1.405  0.030 ± 0.001 −14.35 ± 0.00 0.00   
T558A  0.170   2.33  0.137 ± 0.004 −13.44 ± 0.02 0.91 ± 0.02 
a
  For each experiment, the errors for k1, k−1 and Kd were calculated from the errors in fitting the 
data from a single kinetic series to a Langmuir 1:1 binding model . The fitting model minimizes 
the errors associated with each variable. For all experiments, the errors for k1 and k−1 came out to 
zero when expressed to a suitable number of significant figures. 
b
  n/d, not determined. The data obtained for T558A:pNTD did not fit a kinetic model and was, 






FIGURE 1.  
 
SfbI-5 is intrinsically disordered. A, The 1H, 15N HSQC spectrum of 15N, 13C-labelled SfbI-5. The 
peaks in the spectra were assigned to the 1HN and 15N resonances of SfbI-5 residues using standard 
procedures. Each peak is labelled according to its position in the full-length SfbI-5 sequence. The 
peak annotated I(540) is not native to full-length SfbI, but is directly N-terminal to P541 from native 
SfbI, and the peak annotated R576 is from the side-chain of R576. The other smaller, unassigned 
peaks in close proximity to assigned resonances are likely to arise from residues near a proline as a 
result of the proline being in a cis-conformation. Inset is an enlarged area of the boxed region of the 
spectrum. B, The sequence-corrected SSP score was calculated for SfbI-5 using all available chemical 
shift information. SSP scores of +1 and −1 represent a stable α-helix and β-strand, respectively. A 
score of 0 represents random coil.  
 
FIGURE 2.  
 
Conserved FnBR residues identified with an iterative HMM search of the UniRef90 database. 
Shown above the HMM logo are A, the crystal structures of 2F13F1 and 4F15F1 (purple) bound to 
FnBPA-1 peptides (grey) shown in ribbon representation (23,25). Conserved FnBPA-1 and F1-
module side-chains important in the interaction are shown in stick representation and are coloured 
yellow or cyan, respectively. Hydrogen bonds are shown as black dashed lines and two bridging water 
molecules as grey spheres. B, the sequences of FnBPA-1 (residues 476-514) and the SfbI-5 2−5F1 
binding region (residues 544–578) are aligned to the columns in the HMM logo. Conserved FnBPA-1 
side-chains are also highlighted yellow in the FnBPA-1 sequence, and SfbI-5 residues chosen for 
mutation to alanine are highlighted green. The SfbI-5 residue K556 is underlined: this residue was 
also mutated separately to glutamate. Regions of FnBPA-1 that form a β-strand when bound to 
F1 modules are indicated above the sequences by grey arrows. The logo was drawn with the 
LogoMat-M server, www.sanger.ac.uk/Software/analysis/logomat-m/.  
 
FIGURE 3.  
 
ITC studies of SfbI-5 ( wild-type and mutants) binding to pNTD. A, wild-type, B, K556E, C, 
K556A, D, M562A, E, E553A and F, T558A. In each sub-figure, the top panel shows the 
experimental trace as a solution of SfbI-5 (or SfbI-5 mutant) was titrated into a pNTD solution. When 
a control titration was used to account for heats of dilution it is also shown, but displaced by −0.03 
µcal/s. The bottom panel shows the processed molar heats of binding normalized to the ratio between 
SfbI-5 (or SfbI-5 mutant) to pNTD. For each titration, the curve from non-linear least squares 
regression analysis, using a single-site binding model is shown in grey. Thermodynamic parameters 
derived from these experiments are in Table 1. 
 
FIGURE 4.  
 
Structure of 2F13F1:PyTT5 PyTT5 (green) binds along the E strands of both modules in 2F13F1 
(purple). A, One of the two 2F13F1:PyTT5 complexes in the asymmetric unit. . B, 2F13F1:PyTT5 
structure showing the difference density at a level of 1 sigma (grey) when the PyTT5 molecule is 
deleted. C, The interaction between 2F13F1 and the 3F1-binding and linker regions of PyTT5 shown as 
a stick representation D, The interaction between 2F1 and the 2F1-binding region of PyTT5 shown as a 
stick representation. In both C and D, hydrogen bonds and salt-bridges are black dashes and invariant 
bridging water molecules are shown as grey spheres. Residues mentioned in the text are labelled.  
 
FIGURE 5.  
 
The interface between 2F13F1 and PyTT5. Surface representation of 2F13F1 and PyTT5 (left and 
right, respectively) showing the interface between 2F13F1 and PyTT5. Indicated are the 2F1 and 3F1 
modules, as are the regions of PyTT5 that bind 2F1and 3F1. The schematic above the interfaces shows 
how the complex was opened like a book to reveal the interface. A, The interface is shown at the atom 
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level and is represented as buried and accessible atoms, which are coloured red and blue, respectively. 
B, The interface is shown at the residue level and is represented as core (magenta) and rim (cyan) 
residues. Residue and atom accessibility was calculated from the output of ProFace (50). 
 
FIGURE 6.  
 
Model of the 1−5F1:SfbI-5 complex. Ribbon representation of a model of SfbI-5 (green) in complex 
with 1−5F1 (purple).   
 
FIGURE 7.  
 
SPR studies of GST-SfbI-5 (wild-type and T558A) binding to Fn. Either A, GST-SfbI-5 or B, 
SfbI-5 T558A was immobilised on the chip. Dimeric plasma Fn or pNTD was used as the analyte. 
SPR response curves, baseline corrected, are shown in black; and the best-fits to the data of Langmuir 
1:1 models are shown in grey. Parameters derived from these experiments are shown in Table 3. 
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